Discovery and Structure–Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of <i>Clostridioides difficile</i> Infection
Georg Rueedi, Philippe Panchaud, Astrid Friedli, Jean‐Luc Specklin, Christian Hubschwerlen, A.-C. Blumstein, Patrick Caspers, Michel Enderlin-Paput, Loïc Jacob, Christopher Kohl, Hans H. Locher, Philippe Pfaff, Christine Schmitt, Peter Seiler, Daniel Ritz
Abstract
Clostridioides difficile ( C. difficile ) is one of the leading causes of healthcare-associated infections worldwide. The increasing incidence of strains resistant to currently available therapies highlights the need for alternative treatment options with a novel mode of action. Oxazolidinones that are connected to a quinolone moiety with a pyrrolidine linker, such as compound 1, are reported to exhibit potent broadspectrum antibacterial activity. In an effort to optimize this class of compounds for the treatment of C. difficile infection (CDI), we have identified cadazolid ( 9 ), a first-in-class quinoxolidinone antibiotic, which is a potent inhibitor of C. difficile protein synthesis. In order to achieve narrow-spectrum coverage of clinically most relevant strains without affecting the gut microbiota, an emphasis was placed on abolishing activity against commensals of the intestinal microbiome while retaining good coverage of pathogenic C. difficile, including hypervirulent and epidemic strains.